Search Results for “NHS” – Page 17 – media

Novartis bags EU, UK licences for MS therapy Kesimpta

Novartis has received green lights from both the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab). The drug is a fully human anti-CD20 monoclonal antibody (mAb) thought to work by binding to a distinct epitope on the CD20 molecule, inducing potent B-cell lysis and depletion. It enables faster repletion of B cells versus other anti-CD20 monoclonal antibodies and so may offer flexibility in the management of RMS, according to the drugmaker. As per its licence, Kesimpta can be used to treat adults with relapsing forms of multiple sclerosis (RMS) with active disease, defined by clinical or imaging features. Novartis says it has the potential to become a recognised treatment option for eligible UK patients that can be self-administered, with initial guidance from an appropriately trained healthcare professional, once monthly at home via the Sensoready autoinjector pen. Initial ...
- Source: drugdu
- 161
- April 8, 2021
MS therapy Kesimpta
Novartis UK signs digital partnership with Cievert for chronic disease management 29th March 2021

Novartis UK and digital health company Cievert have announced a digital innovation partnership to help streamline the management of rheumatological and dermatological diseases. The initiative aims to support patient care in rheumatology and dermatology by utilising patient-reported data and allowing clinicians to prioritise appointments on a needs-based model of care. The partnership, which was identified via the Novartis BIOME selection procedure, will see Novartis and Cievert work closely with the NHS to launch pilot programmes across the UK. The digital platform will aim to collaborate with patients, healthcare professionals (HCPs) and the NHS across the UK and support them in three areas. Firstly, the partnership will aim to capture patient digital health records in one platform to reduce misalignment among healthcare teams. Secondly, the programme will aim to coordinate and prioritise appointments based on patient need, rather than routinely scheduled reviews. Lastly, the initiative will collect real-time patient data in ...
- Source: drugdu
- 301
- March 29, 2021
Novartis
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments

Daiichi Sankyo’s cholesterol-lowering drugs Nilemdo and Nustendi have been approved by the UK National Institute for Health and Care Excellence (NICE) for use on the NHS. Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ezetimibe) have been recommended for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia (heterozygous familial and non-familial). It is authorised as an adjunct to diet and when statins are contraindicated or not tolerated, or when the standard cholesterol treatment ezetimibe alone does not control low-density lipoprotein cholesterol (LDL-C) adequately. “Today’s decision is a landmark step forward for patients and the NHS in working towards a national ambition of preventing cardiovascular disease and events in line with the Long Term Plan,” said Manuel Reiberg, managing director, Daiichi Sankyo UK. “We are now more dedicated than ever to reduce the impacts of the UK’s biggest killer through our ongoing collaboration with the medical community and the NHS,” he added. In the UK, ...
- Source: drugdu
- 212
- March 19, 2021
cholesterol-lowering
Tribunal upholds CMA’s decision to fine Lexon £1.2m

The Competition Appeal Tribunal (CAT) has maintained a decision made last year by the UK’s Competition and Markets Authority (CMA) to fine pharmaceutical firm Lexon £1.2m after finding the company guilty of breaking competition law. Last year, the CMA found that Lexon, along with King Pharmaceuticals and Alissa Healthcare Research, had illegally shared commercially sensitive information in an attempt to drive up prices of the antidepressant nortriptyline. The CMA concluded that from 2015 to 2017 – when the cost of the drug was decreasing – the three companies exchanged information about prices, the volumes they were supplying and Alissa’s plans to enter the market. The CMA then fined all three companies, fining Lexon a total of £1.2m – however, Lexon maintained it had not broken the law and appealed the decision and fine. However, the CAT has decided to uphold the CMA’s original finding that Lexon broke competition law and ...
- Source: drugdu
- 204
- March 1, 2021
Tribunal
New social media campaign launched to support COVID-19 vaccine roll-out in the UK

A new social media campaign, launched by the UK government and the NHS, will allow people to show their support for the COVID-19 vaccine roll-out from today. The initiative will enable users to update their social media profiles with specially designed profile frames and graphics. This allows people to show either that ‘I’ve had my vaccine’ or make a pledge that ‘I will get my vaccine’ in an effort to bolster the nationwide vaccination programme. The range of Facebook frames and Instagram GIFs will be ready for use on social media from 19 February, and will be available in 13 languages from 22 February. “We know people are turning to social media more than ever to stay in touch with family and friends,” said Health and Social Care Secretary Matt Hancock. “These new graphics will make it easy for people to share their support for the jab and thank the ...
- Source: drugdu
- 370
- February 23, 2021
Covid-19 vaccine
Research finds decrease in radiotherapy treatments due to COVID-19

New research has revealed ‘dramatic changes’ in the delivery of radiotherapy treatments for cancer during the first wave of the COVID-19 pandemic in England. The study – led by the University of Leeds with Public Health England and the Royal College of Radiologists – is the first to evaluate the impact of the pandemic on radiotherapy services in England. Researchers discovered that the use of much shorter radiotherapy courses increased – in particular for breast cancer patients. The use of a shorter treatment course went from 0.2% of all breast cancer radiotherapy courses in April 2019, up to 60.0% of all courses in April 2020. The change to shorter courses of treatment was also observed in other types of cancer, with clinicians likely making the switch to keep patients safe and services running during the pandemic. According to the researchers, this change was made possible in part by results of ...
- Source: drugdu
- 239
- January 28, 2021
Covid-19
Hopes rise for approval of coronavirus vaccine by end of year

US expert Dr Anthony Fauci says it should be known by early December if vaccine is safe to roll out Nurses on a Covid-19 ward in Merseyside, north-west England. Healthcare workers and people most at risk will be prioritised for first doses of a vaccine. Photograph: Peter Byrne/PA Hopes are rising that a coronavirus vaccine will be approved by the end of the year, with healthcare workers receiving their first dose in early 2021. Dr Anthony Fauci, the US’s leading expert in infectious diseases, said on Sunday it should be known by the end of November or early December if a vaccine was safe and effective. The Irish government added to the growing optimism that a vaccine would soon be available. “I’m increasingly optimistic, as is government, that we will see a vaccine approved in the next couple of months and that in the first half or first quarter of next ...
- Source: drugdu
- 220
- October 27, 2020
Covid-19
Scientists Invent Lamp for Treatment of Chronic Ulcers

The University of Manchester and Salford Royal NHS Trust researchers have built a lamp to treat chronic ulcers.
- Source: The Verdict
- 466
- July 31, 2018
chronic ulcers Researches
System C Signs Contract to Offer Pooled Child Health Record in South West England

System C has signed a contract to develop a collective child health information system in the South West of England. 708,000 child health records from South Gloucester, Bristol, Somerset and North Somerset, Devon, Torbay, Plymouth and Cornwall will be put to use by its CarePlus software.
- Source: DigitalHealth
- 755
- July 29, 2018
digital health EHR Researches
HPV Vaccination for Both Girls & Boys

Government advisors are recommending that the national HPV immunization programme in England should include both boys and girls. The Joint Committee of Vaccinations and Immunisations (JCVI) believes that this would be a cost-effective option for preventing HPV-related diseases in boys and further improves public health.
- Source: PharmaTimes
- 677
- July 26, 2018
HPV vaccine Policies STD

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.